SCHEMBL29599997

SCHEMBL29599997

CC(Cc1ccc(C2(C)OCCO2)s1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 6/20 0.41
TMPRSS15 P98073 6/20 0.41
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
APAF1 O14727 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 1/20 0.35
RXRA P19793 1/20 0.33
NR4A2 P43354 1/20 0.33
GLA P06280 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CTSD P07339 1/20 0.31
BACE1 P56817 1/20 0.31
SLC22A12 Q96S37 2/20 0.31
TBXAS1 P24557 2/20 0.31
STING1 Q86WV6 2/20 0.31
HCAR3 P49019 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1705828 0.78 HPGD (0.41) ALDH1A1POLBMAPTRECQLL3MBTL1
SCHEMBL29599437 0.76 STING1 (0.36) PRSS1TMPRSS15RXRASLC22A12STING1
SCHEMBL2921395 0.76 PRSS1 (0.47) PRSS1TMPRSS15ALDH1A1KDM4EAPAF1
SCHEMBL29600076 0.76 LMNA (0.43) ALDH1A1POLBRECQLL3MBTL1HPGD
SCHEMBL29599975 0.74 PRSS1 (0.38) PRSS1TMPRSS15SMN1; SMN2STING1
SCHEMBL855028 0.74 MEN1 (0.37) ALDH1A1MAPTHPGDGLA
SCHEMBL29600279 0.72 PRSS1 (0.39) PRSS1TMPRSS15KDM4EAPAF1POLB
SCHEMBL856231 0.71
SCHEMBL855952 0.71 CYP2E1 (0.36)
SCHEMBL28388882 0.69 PRSS1 (0.44) PRSS1TMPRSS15ALDH1A1KDM4EAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 PRSS1 3939/4885TMPRSS15 4683/4885ALDH1A1 555/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 PRSS1 3760/4885TMPRSS15 4593/4885ALDH1A1 790/4885
US-20240132519-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 PRSS1 4085/4885TMPRSS15 4448/4885ALDH1A1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.